Inflammation Research

, Volume 67, Issue 3, pp 203–205 | Cite as

Baicalin in flavocoxid may act against hepatitis B virus via a pro-inflammatory pathway

  • Salvatore Chirumbolo
Letter to the Editor

Dear Editor,

The recent paper by Pollicino and colleagues showed that a new synthetic flavonoid formula (Flavocoxid) containing baicalin and catechin has a potent antiviral activity against hepatitis B virus (HBV) infection [1]. Flavocoxid (FLAV), which is known to be an anti-inflammatory natural product [2, 3], is a FDA-regulated proprietary blend of purified plant-derived flavonoids (Limbrel®) for use as a supplementary nutraceutical in clinical nutrition studies and contains baicalein-7-O-glucuronide and catechins [3].

It is well known that baicalin inhibits the HBV viral RNA [4]. This flavone-glucuronide dampens dose-dependently the production of HBV 2.1, 2.4 and 3.5 kb HBV RNAs, the latter being the template for the synthesis of HBV DNA [4]. Furthermore, catechins are able to inhibit HBV infection via further biochemical pathways [5, 6, 7]. It is not so surprising, therefore, that FLAV may act against HBV, blunting the replication of viral DNA and targeting other vital steps...


Compliance with ethical standards

Conflict of interest

The author states he has no conflict of interest.


  1. 1.
    Pollicino T, Musolino C, Irrera N, Bitto A, Lombardo D, Timmoneri M, Minutoli L, Raimondo G, Squadrito G, Squadrito F, Altavilla D. Flavocoxid exerts a potent antiviral effect against hepatitis B virus. Inflamm Res. 2017. Scholar
  2. 2.
    Bitto A, Squadrito F, Irrera N, Pizzino G, Pallio G, Mecchio A, Galfo F, Altavilla D. Flavocoxid, a nutraceutical approach to blunt inflammatory conditions. Mediators Inflamm. 2014;2014:790851.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Altavilla D, Squadrito F, Bitto A, Polito F, Burnett BP, Di Stefano V, Minutoli L. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages. Br J Pharmacol. 2009;157(8):1410–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Huang H, Zhou W, Zhu H, Zhou P, Shi X. Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs. Toxicol Appl Pharmacol. 2017;323:36–43.CrossRefPubMedGoogle Scholar
  5. 5.
    Xu J, Gu W, Li C, Li X, Xing G, Li Y, Song Y, Zheng W. Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha. J Nat Med. 2016;70(3):584–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Pang JY, Zhao KJ, Wang JB, Ma ZJ, Xiao XH. Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro. J Zhejiang Univ Sci B. 2014;15(6):533–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    He W, Li LX, Liao QJ, Liu CL, Chen XL. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication-inducible cell line. World J Gastroenterol. 2011;17(11):1507–14.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Stonāns I, Stonāne E, Russwurm S, Deigner HP, Böhm KJ, Wiederhold M, Jäger L, Reinhart K. HepG2 human hepatoma cells express multiple cytokine genes. Cytokine. 1999;11(2):151–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Nikolaidou-Neokosmidou V, Zannis VI, Kardassis D. Inhibition of hepatocytes nuclear factor 4 transcriptional activity by the nuclear factor kappa B pathway. Biochem J. 2006;398(3):439–50.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Park SG, Ryu HM, Lim SO, Kim YI, Hwang SB, Jung G. Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase. Gastroenterology. 2005;128(7):2042–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Chu M, Xu L, Zhang MB, Chu ZY, Wang YD. Role of baicalin in anti-influenza virus A as a potent inducer of IFN-gamma. Biomed Res Int. 2015;2015:263630.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, Zou W. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012;56(4):1342–51.CrossRefPubMedGoogle Scholar
  13. 13.
    Hu G, Xue J, Liu J, Zhang T, Dong H, Duan H, Yang Z, ren X, Mu X. Baicalin baicalin induces IFN-α/β and IFN-γ expressions in cultured mouse pulmonary microvascular endothelial cells. J Integrat Agric. 2012;11(4):646–54.CrossRefGoogle Scholar
  14. 14.
    Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol. 2015;21(15):4644–51.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Palumbo GA, Scisciani C, Pediconi N, Lupacchini L, Alfalate D, Guerrieri F, Calvo L, Salerno D, Di Cocco S, Levrero M, Belloni L. IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLoS One. 2015;10(11):e0142599.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nakamura N, Hayasaka S, Zhang XY, Nagaki Y, Matsumoto M, Hayasaka Y, Terasawa K. Effects of baicalin, baicalein, and wogonin on interleukin-6 and interleukin-8 expression, and nuclear factor-kappab binding activities induced by interleukin-1beta in human retinal pigment epithelial cell line. Exp Eye Res. 2003;77(2):195–202.CrossRefPubMedGoogle Scholar
  17. 17.
    Norris CA, He M, Kang LI, Ding MQ, Radder JE, Haynes MM, Yang Y, Paranjpe S, Bowen WC, Orr A, Michalopoulos GK, Stolz DB, Mars WM. Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli. PLoS One. 2014;9(4):e96053.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Guo Q, Zhao L, You Q, Yang Y, Gu H, Song G, Lu N, Xin J. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res. 2007;74(1):16–24.CrossRefPubMedGoogle Scholar
  19. 19.
    Liu Y, Gao LF, Liang XH, Ma CH. Role of Tim-3 in hepatitis B virus infection: an overview. World J Gastroenterol. 2016;22(7):2294–303.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G, Gilson R, ChinAleong J, Kennedy P, Maini MK. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One. 2012;7(10):e47648.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ju Y, Hou N, Zhang XN, Zhao D, Liu Y, Wang JJ, Luan F, Shi W, Zhu FL, Sun WS, Zhang LN, Gao CJ, Gao LF, Liang XH, Ma CH. Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8 + T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol. 2009;6(1):35–43.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Neurological and Movement SciencesUniversity of VeronaVeronaItaly

Personalised recommendations